#### **Emad Eldin Abdalla Shash**

# **PERSONAL DATA:**

Full Name Emad Eldin Abdalla Shash

Date of birth: 12/6/1981
Marital Status: Married

**Address:** 6 Bedayet El-Manial St, Roda. 11451, Cairo, Egypt.

**Telephone:** Home +(202) 23130860

+(202) 23620041 Cellular +(202) 0122365498

**Email:** emadshash@gmail.com



### **ACADEMIC QUALIFICATIONS:**

**Master of Science (M.Sc.) in Medical Oncology** (November/2008). National Cancer Institute, Cairo University. Dissertation title: "Prognostic & Predictive markers of HCC".

**Bachelor (M.B., B.Ch) of Medicine and Surgery** December/2004. (The Egyptian equivalent to an M.D). Excellent with honors. Faculty of Medicine, Cairo University.

# **ACADEMIC and PROFESSIONAL EXPERIENCE:**

Medical Oncologist and Assistant Lecturer of Medical Oncology— NCI, Cairo University. (June 2009 – Present)

Postgraduate training — Kasr Al Aini Hospital, Cairo University (2008)

Resident of Medical Oncology - National Cancer Institute, Cairo University (May 2006- May 2009)

Internship — Kasr Al Aini Hospitals, Cairo University (2005-2006)

\* Clinical Unit Visit Fellowship at European Institute of Oncology, Milan, Italy (Start date September 2010) Fertility preservation in Cancer patients. Under the mentorship of Dr. Fedro Peccatori. (6 weeks duration).

### MEMBERSHIP OF PROFESSIONAL AND SCIENTIFIC SOCIETIES:

Egyptian Cancer Society (ECS)
Egyptian Hemato-oncology group (EHOG)
European Society of Medical Oncology (ESMO)
European Arab Society of Oncology (EASO)

#### **HONORS AND AWARDS:**

NCI representative of residents to attend President Obama speech at the Cairo University, June 2009.

## **RECENT SEMINARS & PRESENTATIONS:**

### Continuous medical education courses (CME):

GCP & Medical writing workshop. Tunis, Tunisia, April 2010.

Online GCP intensified course for clinical research investigators, April 2010.

9<sup>th</sup> ESO-ESMO master class of clinical oncology. Ermatingen, Switzerland, March 2010

Palliative integrated oncology advanced EPEC-Oncology course, Cairo, Egypt, April 2009.

Basic principles of genetics, pathology, cytology, tissue culture, surgical oncology, radiotherapy and statistics. 2007-2008

### Seminars and presentations:

- Castrate Resistant Prostate case presentation. . Emad Shash, MD. Ermatingen, Switzeralnd, March 2010. 9<sup>th</sup> ESO-ESMO Master class.
- *Von-Hippel-Lindau Syndrome case presentation*. Emad Shash, MD. Amman, Jordan, October 2009. EASO Urogenital Course.
- Morbidity and mortality case presentations every 3 month regularly as part of the residents program at the Medical oncology department (over the past 3 years)
- Active Participation in the clinical grand round at NCI, Cairo, Egypt and giving seminar presentations on different topics.

### **EDITORIALS & PUBLICATIONS:**

- -Metastatic Colorectal Cancer: Are we talking about curability? Mohamed Abdulla and Emad Shash. *Advances in Oncology*; March 2010; vol. 5: issue 1: 1-4
- Ongoing original article about Bone Lymphoma (New Categorization of Egyptian Bone Lymphoma patients: Single Institutional study)
- GIST: The past, the present and the future (review article submitted and will be published in September 2010)

### **RESEARCH ACTIVITIES:**

Participation in ongoing phase II & III global clinical trials in the field of both solid and hematology malignancies, in addition to participation of local investigator initiated clinical research projects.

- MERITS study by Egyptian Foundation For Cancer Research: Multi-Center, Middle East, Phase-II Study, Non-Comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients with Advanced Renal Cell Carcinoma to Evaluate the Efficacy and Tolerability of the Drug (Sub-Investigator)
- **NSABP B-44-I, CIRG (TRIO) 011, Roche BO20906, BETH:** A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (Sub-Investigator)
- CRAD001Y2301, Novartis: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopuasal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (Coordinator)
- CRAD001L2201, Novartis: A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney (Sub-Investigator)
- **M10-963:** An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)(**Sub-Investigator**)

**LANGUAGES:** English (fluent), Arabic (mother tongue) & French (moderate level).

### **REFERENCES:**

To be listed upon request